- Home
- SST vs NVNO Comparison
SST vs NVNO Comparison
Compare SST & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- NVNO
- Stock Information
- Founded
- SST 2013
- NVNO 1987
- Country
- SST United States
- NVNO United States
- Employees
- SST N/A
- NVNO N/A
- Industry
- SST Diversified Commercial Services
- NVNO Medical/Dental Instruments
- Sector
- SST Consumer Discretionary
- NVNO Health Care
- Exchange
- SST Nasdaq
- NVNO Nasdaq
- Market Cap
- SST 23.3M
- NVNO 71.0M
- IPO Year
- SST N/A
- NVNO N/A
- Fundamental
- Price
- SST $6.24
- NVNO $4.20
- Analyst Decision
- SST Strong Buy
- NVNO
- Analyst Count
- SST 1
- NVNO 0
- Target Price
- SST $500.00
- NVNO N/A
- AVG Volume (30 Days)
- SST 365.1K
- NVNO 93.8K
- Earning Date
- SST 08-07-2025
- NVNO 07-30-2025
- Dividend Yield
- SST N/A
- NVNO N/A
- EPS Growth
- SST N/A
- NVNO N/A
- EPS
- SST N/A
- NVNO N/A
- Revenue
- SST $333,521,000.00
- NVNO N/A
- Revenue This Year
- SST N/A
- NVNO N/A
- Revenue Next Year
- SST $8.39
- NVNO N/A
- P/E Ratio
- SST N/A
- NVNO N/A
- Revenue Growth
- SST N/A
- NVNO N/A
- 52 Week Low
- SST $2.90
- NVNO $2.03
- 52 Week High
- SST $15.70
- NVNO $6.48
- Technical
- Relative Strength Index (RSI)
- SST 53.33
- NVNO 59.82
- Support Level
- SST $5.20
- NVNO $3.89
- Resistance Level
- SST $6.82
- NVNO $4.40
- Average True Range (ATR)
- SST 2.03
- NVNO 0.24
- MACD
- SST -0.18
- NVNO -0.02
- Stochastic Oscillator
- SST 14.14
- NVNO 64.06
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.